About a year ago, I kept seeing the same phrase pop up everywhere — in news headlines, in podcasts, in a half-overheard conversation at a café in Melbourne: psychedelic-assisted therapy. People talked about it like it was either the biggest breakthrough in mental health since Prozac or an expensive bit of wishful thinking dressed up in a lab coat. I had no idea which.

So I did what any reasonably curious psychologist does at 11pm. I started reading. Here’s what I found, written for the version of me who, a year ago, couldn’t have told you the difference between psilocybin and a probiotic.

So what actually is it?

Let’s clear up the most common misconception first: psychedelic-assisted therapy is not “take some mushrooms and feel better.” The drug is only one ingredient, and arguably not even the main one.

The model goes roughly like this. You have several preparation sessions with trained therapists, where you build trust and set intentions. Then you have one or more dosing sessions — these can run six to eight hours — where you take the substance in a calm, supervised room (think soft lighting, a comfortable couch, eye mask, curated playlist) with two therapists (often a male and a female) present the entire time. Afterwards come the integration sessions, where you process whatever came up and try to translate the experience into actual changes in your life.

The two substances getting the most attention are psilocybin (the active compound in magic mushrooms) and MDMA (the same chemical family as the party drug ecstasy, though pharmaceutical-grade and used very differently here). The theory, very simplified, is that these drugs temporarily loosen rigid patterns of thinking and increase emotional openness, creating a window in which therapy can do deeper work than it otherwise could. MDMA in particular seems to dial down the fear response enough that people can revisit trauma without being overwhelmed by it.

The key thing to hold onto: the therapy is the treatment. The drug just opens the door.

Why Australia is suddenly a global story

Here’s the part that surprised me most. Australia isn’t tagging along behind the rest of the world on this — it’s out in front.

In February 2023, the Therapeutic Goods Administration (the TGA, our equivalent of the US FDA) made a decision that genuinely shocked the field. From 1 July 2023, it allowed approved psychiatrists to prescribe psilocybin for treatment-resistant depression and MDMA for post-traumatic stress disorder (PTSD). That made Australia the first country in the world to formally recognise and regulate both substances as medicines at a national level, rather than confining them to clinical trials.

For these two specific uses, psilocybin and MDMA were moved into Schedule 8 — the same controlled-but-prescribable category as strong painkillers. For any other use they remain Schedule 9, which is to say prohibited. So this is a narrow, tightly fenced opening, not a free-for-all.

By early 2026 the program had grown from a standing start: according to data the TGA released under a Freedom of Information request, around 87 people had been treated with MDMA for PTSD and 47 with psilocybin for depression as of mid-September 2025, with the cumulative figure climbing toward roughly 200 patients soon after. Treatment is now available in six of Australia’s eight states and territories, more than 600 therapists have completed recognised training, and the number of authorised prescribing psychiatrists is in the dozens. In May 2026 the TGA went further, updating its framework to widen which professionals can act as therapists and to allow a broader range of treatment settings — a sign the regulator intends to scale the program up, not wind it back.

There’s even a small but striking detail in the reporting: a handful of patients have reportedly travelled to Australia from overseas to access the treatment, because there are so few legal pathways elsewhere.

What can it actually treat?

Officially, in Australia, just two things: treatment-resistant depression (psilocybin) and PTSD (MDMA). “Treatment-resistant” is doing real work in that sentence — it generally means you’ve tried other established treatments and they haven’t worked. This is positioned as a last-resort option for people who’ve run out of others, not a first port of call.

In research settings around the world, scientists are also investigating psychedelics for end-of-life anxiety in terminal illness, alcohol and other substance use disorders, anorexia, and obsessive-compulsive disorder, among others. But that’s research. Outside of a clinical trial, those aren’t approved uses anywhere, and it’s worth being sceptical of any clinic implying otherwise.

How would you actually access it?

This is where the gap between the headlines and reality gets wide.

You can’t book yourself in. The pathway runs through an Authorised Prescriber — a psychiatrist who has jumped through a genuinely demanding set of hoops. To qualify, a psychiatrist must be a Fellow of the Royal Australian and New Zealand College of Psychiatrists, get a clinical protocol approved by a Human Research Ethics Committee, and then obtain authorisation from the TGA. It’s deliberately rigorous, which is partly why there are still only dozens of them.

There’s also a quietly important legal wrinkle: it is illegal in Australia for clinics or prescribers to advertise these treatments to the public. So you won’t (legally) see billboards. The intended route is a referral conversation with a GP or psychiatrist, usually after other treatments have been exhausted. From there it’s screening, preparation, the dosing sessions, and integration — a process measured in weeks to months, not a single appointment.

Let’s talk about the money

Here’s the wall most people hit: it’s expensive. Reporting in Australia has put the cost of a full course of MDMA-assisted therapy at around $30,000, largely out of pocket. There are no psilocybin or MDMA products on the official Australian Register of Therapeutic Goods, and the treatment isn’t broadly covered by Medicare or private health insurance, so the cost falls on the patient.

That price tag has become the central equity criticism of the whole program. A treatment that early data suggests might help people for whom nothing else has worked is, for now, mostly available to those who can find $30,000. The one notable exception is veterans: the Australian government has begun moving to fund MDMA and psilocybin treatment for eligible veterans through the Department of Veterans’ Affairs, with support funded over four years from 2025–26. For everyone else, affordability remains the single biggest barrier.

The promises (why people are excited)

The optimism isn’t coming from nowhere. In clinical trials, the effect sizes for these treatments have at times been large — large enough to make serious researchers sit up. For people with treatment-resistant depression or chronic PTSD, conditions that can be devastating and stubbornly unresponsive, even a moderate chance of meaningful relief is a big deal.

Two features make psychedelics genuinely different from a daily antidepressant. First, the speed: improvements can show up after just one to three sessions rather than weeks of daily pills. Second, the durability: at least some patients report benefits lasting months from a small number of sessions, suggesting the drug is catalysing a lasting psychological shift rather than just managing symptoms day to day.

And the momentum behind the science is real. In February 2026, COMPASS Pathways announced that its second large Phase 3 trial of psilocybin for treatment-resistant depression had met its primary endpoint, following a positive first trial in 2025 — putting it on a path toward a possible US approval decision in late 2026 or early 2027, which would make it the first classic psychedelic ever approved by the FDA.

The controversy (why others are nervous)

Now for the cold water, because there’s plenty, and the honest answer is that the experts themselves are split.

Was Australia too fast? A vocal group of researchers and clinicians argued at the time that the TGA’s 2023 decision was premature — that it ran ahead of the evidence, with limited efficacy and safety data and unclear protocols for the clinicians delivering it. Surveys of Australian mental health providers since then have found broad openness to the idea, but persistent worries about safety and weak evidence, especially among psychiatrists — some of whom have gone as far as calling the approach pseudoscientific. Psychologists tend to be more enthusiastic than psychiatrists, which tells you something about how unsettled the professional consensus is.

The blinding problem. This one is subtle but serious. In a good drug trial, neither patient nor researcher should know who got the real drug versus a placebo. But with a substance that produces vivid, unmistakable effects, almost everyone knows whether they got the active drug. This “functional unblinding” can inflate results, because expectation and enthusiasm do real work in mental health — and critics argue it makes the trial data harder to trust than the headline numbers suggest.

The American cautionary tale. While Australia opened the door, the United States slammed one shut. In August 2024 the FDA declined to approve MDMA-assisted therapy for PTSD, asking the sponsor, Lykos Therapeutics, to run another Phase 3 trial. The reasons, laid out in a letter the FDA made public in September 2025, included concerns about trial integrity, the blinding issue above, and — most damagingly — alleged ethical violations at one trial site that led a journal to retract three papers. It was a genuine shock to a field that had assumed approval was imminent, and a reminder that promising data and clean data are not the same thing.

The therapy is the wild card. Remember that the drug is supposedly the smaller half of the equation. Yet a February 2026 analysis flagged that Australia still lacks a national accreditation framework for therapists and standardised tools to ensure the therapy itself is delivered consistently and well. When the therapeutic container matters this much, and when patients are at their most vulnerable mid-session, the absence of agreed standards is not a small thing. There have also been documented cases internationally of boundary violations by therapists during these intense, intimate sessions — which is exactly why the guardrails matter.

The rest of the world, briefly

Australia’s national medical model is unusual. Elsewhere the landscape is a patchwork. In the US, psilocybin remains illegal federally, but Oregon and Colorado run state-licensed supervised service centres (Oregon has reportedly served around 16,000 people), and New Mexico became the first state to legalise medical psilocybin through legislation in 2025. Switzerland, Canada, and Germany allow narrow medical access. Countries like the Netherlands and Jamaica host legal-or-tolerated retreats that operate outside a medical framework entirely — which comes with very different, and fewer, protections.

Where I landed

After all the reading, here’s my honest take as a clinical psychologist, for whatever that’s worth.

This is one of the most genuinely promising developments in mental health in a generation, and it’s an area where the hype has plainly outrun the evidence in places, and both of those things can be true at once. The stories of people whose lives were turned around after years of suffering are real and moving. So are the concerns about rushed approvals, shaky trial design, eye-watering costs, and unregulated therapists. The grown-up position seems to be cautious hope: watch the next round of trial data, watch how Australia’s real-world program performs now that hundreds of people are going through it, and resist the pull of anyone selling certainty in either direction.

What I won’t do is pretend it’s settled. It isn’t. But it’s no longer a fringe curiosity either — it’s happening, right now, in clinics a short drive from where I’m sitting.

---

A note: this is a general overview written by a curious non-expert psychologist, not medical advice. Psychedelic-assisted therapy is a serious medical treatment with real risks, and these substances remain illegal outside the narrow, supervised pathways described here. If you’re struggling with depression, PTSD, or any mental health condition, please talk to your GP or reach out to one of our psychologists for an appointment.